Market Overview

Citigroup Reiterates Buy Rating, $20 PT on Amarin Corporation

Share:
Related AMRN
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4
Stocks to Watch for October 23, 2014
Amarin: Modeling Its Cash Balance Trajectory To 2017 (Seeking Alpha)

In a report published Friday, Citigroup reiterated its Buy rating and $20.00 price target on Amarin Corporation (NASDAQ: AMRN).

Citigroup noted, “We were not surprised by AMRN's initiation of hiring a Vascepa salesforce based on prior management guidance. However, we believe the concurrent establishment of a $100M debt instrument despite ending 3Q with $215M in cash will inject added uncertainty around both next Friday‘s (12/14) expected FDA exclusivity decision for Vascepa getting NCE, and the relative interest level of potential partners. We expect these actions to increase the nearterm speculation and volatility for AMRN shares, however our projections for Vascepa are unchanged as we previously valued AMRN based on a stand-alone scenario.”

Amarin Corporation closed on Thursday at $11.95.

Latest Ratings for AMRN

DateFirmActionFromTo
Feb 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
Nov 2014CitigroupMaintainsNeutral
May 2014CitigroupDowngradesBuyNeutral

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Reiteration Analyst Ratings

 

Related Articles (AMRN)

Around the Web, We're Loving...

Get Benzinga's Newsletters